Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
Author:
Affiliation:
1. Teikyo Academic Research Center, Teikyo University
2. Cardiovascular Medical, Sanofi
3. Clinical Sciences and Operations, Sanofi
4. PCSK9 Development and Launch Unit, Sanofi
Publisher
Japan Atherosclerosis Society
Subject
Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine
Link
https://www.jstage.jst.go.jp/article/jat/26/3/26_45070/_pdf
Reference39 articles.
1. 1) Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK and Danesh J: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010; 375: 2215-2222
2. 2) Haffner SM, Lehto S, Ronnemaa T, Pyorala K and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234
3. 3) Engelen SE, van der Graaf Y, Stam-Slob MC, Grobbee DE, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FLJ, Westerink J and SMART study group: Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. Int J Cardiol, 2017; 248: 301-307
4. 4) Verges B: Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, 2015; 58: 886-899
5. 5) Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA and Zamorano JL: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016; 37: 2999-3058
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of PCSK9 inhibitors in patients with diabetes: A systematic review and meta-analysis;Nutrition, Metabolism and Cardiovascular Diseases;2023-09
2. Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events;Frontiers in Cardiovascular Medicine;2023-06-26
3. Comorbidities with Familial Hypercholesterolemia (FH): A Systematic Review;Current Problems in Cardiology;2023-05
4. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials;European Heart Journal - Cardiovascular Pharmacotherapy;2023-03-27
5. Clinical Efficacy of Proprotein Convertase Synthase Kexin Type 9 Inhibition in Persons with Diabetes Mellitus;Contemporary Diabetes;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3